Sialic acid–containing glycoproteins

Sialic acid–containing glycoproteins, or sialoglycoproteins, represent a broad category of proteins modified by the addition of terminal sialic acid residues to their glycan chains. These molecules are ubiquitous on mammalian cell surfaces and secreted proteins, where they play pivotal roles in cell-cell recognition, immune signaling, and the regulation of protein stability and half-life (Varki, A., 2008, Trends in Molecular Medicine). In the immune system, sialoglycoproteins act as ligands for Siglecs, helping the body distinguish between self and non-self and maintaining immune homeostasis (Crocker et al., 2007, Nature Reviews Immunology). Pathologically, many pathogens, including the influenza virus, exploit these glycoproteins as attachment points for infection, while cancer cells often exhibit hypersialylation to evade immune detection and promote metastasis (Pearce & Läubli, 2016, Glycobiology). Therapeutic intervention involving sialoglycoproteins typically focuses on either preventing their modification or blocking their interactions with receptors. For instance, neuraminidase inhibitors like oseltamivir prevent the cleavage of sialic acids, which is essential for the release of viral progeny from host cells (Byrd-Leotis et al., 2017, Trends in Microbiology). In oncology, emerging therapies such as sialidase fusion proteins aim to strip sialic acids from the tumor surface to unmask the cancer cells for immune attack.

Other names

SialoglycoproteinsSialylated glycoproteinsN-acetylneuraminic acid-containing proteins

Inhibition of neuraminidase enzymes to prevent the cleavage of sialic acid residues from glycoproteins; enzymatic desialylation of cell surfaces to enhance immune activation; blocking of selectin-sialoglycoprotein interactions to reduce inflammation.